Hepatocyte transporter expression in FNH and FNH-like nodule: Correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images

Japanese Journal of Radiology

Volumn 30, Issue 6, 2012, Pages 499-508

  Yoneda, Norihide ^a   Matsui, Osamu ^a   Kitao, Azusa ^a   Kita, Ryuuichi ^b   Kozaka, Kazuto ^a   Koda, Wataru ^a   Kobayashi, Satoshi ^a   Gabata, Toshifumi ^a   Ikeda, Hiroko ^a   Sato, Yasunori ^c   Nakanuma, Yasuni ^c  

^a KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

EOB MRI; FNH; FNH like nodule; HB phase; OATP8

Indexed keywords

GADOXETIC ACID; MULTIDRUG RESISTANT PROTEIN 1; MULTIDRUG RESISTANT PROTEIN 2; MULTIDRUG RESISTANT PROTEIN 3; ORGANIC ANION TRANSPORTER POLYPEPTIDE 8; PEPTIDES AND PROTEINS; POLYPEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; FOCAL NODULAR HYPERPLASIA LIKE LESION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL; MALE; NODULAR HYPERPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; FOCAL NODULAR HYPERPLASIA; GADOLINIUM DTPA; HEPATOCYTES; HUMANS; IMAGE ENHANCEMENT; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84866007133     PISSN: 18671071     EISSN: 1867108X     Source Type: Journal    
DOI: 10.1007/s11604-012-0085-4     Document Type: Article

References (28)

1. Vogl T, Kümmel S, Hammerstingl R, Schellenbeck M, Schumacher G, Balzer T, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology. 1996; 200(1):59-67.
2. Bluemke D, Sahani D, Amendola M, Balzer T, Breuer J, Brown JJ, et al. Efficacy and safety of MR imaging with liver-specific contrast agent: U.S. multicenter phase III study. Radiology. 2005;237(1):89-98.
3. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol. 2004;14(4):559-578.
4. Schuhmann-Giampieri G, Schmitt-Willich H, Press W, Negishi C, Weinmann H, Speck U. Preclinical evaluation of Gd-EOBDTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology. 1992;183(1):59-64.
5. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, et al. Enhancement of focal liver lesions at gadoxetic acidenhanced MR imaging: correlation with histopathologic findings and spiral CT - initial observations. Radiology. 2005;234(2): 468-478.
6. Hamm B, Staks T, Mühler A, Bollow M, Taupitz M, Frenzel T, et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology. 1995;195(3):785-792.
7. Reimer P, Rummeny E, Shamsi K, Balzer T, Daldrup HE, Tombach B, et al. Phase II clinical evaluation of Gd-EOB-DTPA: dose, safety aspects, and pulse sequence. Radiology. 1996; 199(1):177-183.
8. Zech C, Grazioli L, Breuer J, Reiser M, Schoenberg S. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43(7):504-511.
9. Vander Borght S, Libbrecht L, Blokzijl H, Faber KN, Moshage H, Aerts R, et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol. 2005;207(4):471-482.
10. Nakanuma Y. Non-neoplastic nodular lesions in the liver. Pathol Int. 1995;45(10):703-714.
11. Terminology of Nodular Hepatocellular Lesions. International working party. Hepatology. 1995;22(3):983-993.
12. Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, et al. Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol. 2007;46(3):521-527.
13. Sugihara S, Nakashima O, Kiyomatsu K, Ijiri M, Edamitsu O, Kojiro M. A case of liver cirrhosis with a hyperplastic nodular lesion. Acta Pathol Jpn. 1990;40(9):699-703.
14. Terada T, Kitani S, Ueda K, Nakanuma Y, Kitagawa K, Masuda S. Adenomatous hyperplasia of the liver resembling focal nodular hyperplasia in patients with chronic liver disease. Virchows Arch A Pathol Anat Histopathol. 1993;422(3):247-252.
15. Quaglia A, Tibballs J, Grasso A, Prasad N, Nozza P, Davies SE, et al. Focal nodular hyperplasia-like areas in cirrhosis. Histopathology. 2003;42(1):14-21.
16. An H, Illei P, Diflo T, John D, Morgan G, Teperman L, et al. Scirrhous changes in dysplastic nodules do not indicate highgrade status. J Gastroenterol Hepatol. 2003;18(6):660-665.
17. Nakashima O, Kurogi M, Yamaguchi R, Miyaaki H, Fujimoto M, Yano H, et al. Unique hypervascular nodules in alcoholic liver cirrhosis: identical to focal nodular hyperplasia-like nodules? J Hepatol. 2004;41(6):992-998.
18. Wanless I, Mawdsley C, Adams R. On the pathogenesis of focal nodular hyperplasia of the liver. Hepatology. 1985;5(6):1194-1200.
19. Bioulac-Sage P, Balabaud C, Wanless I. Diagnosis of focal nodular hyperplasia: not so easy. Am J Surg Pathol. 2001; 25(10):1322-1325.
20. Welch T, Sheedy PF 2nd, Johnson C, Stephens DH, Charboneau JW, Brown ML, et al. Focal nodular hyperplasia and hepatic adenoma: comparison of angiography, CT, US, and scintigraphy. Radiology. 1985;156(3):593-595.
21. Carlson S, Johnson C, Bender C, Welch T. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol. 2000;174(3): 705-712.
22. Brancatelli G, Federle M, Grazioli L, Blachar A, Peterson M, Thaete L. Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology. 2001; 219(1):61-68.
23. Miyayama S, Matsui O, Ueda K, Kifune K, Yamashiro M, Yamamoto T, et al. Hemodynamics of small hepatic focal nodular hyperplasia: evaluation with single-level dynamic CT during hepatic arteriography. AJRAmJ Roentgenol. 2000;174(6):1567-1569.
24. Giovanoli O, Heim M, Terracciano L, Bongartz G, Ledermann HP. MRI of hepatic adenomatosis: initial observations with gadoxetic acid contrast agent in three patients. AJR Am J Roentgenol. 2008;190(5):W290-W293.
25. Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acidenhanced MR imaging - correlation with molecular transporters and histopathologic features. Radiology. 2010;256(3):817-826.
26. Leonhardt M, Keiser M, Oswald S, Kühn J, Jia J, Grube M, et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos. 2010;38(7):1024-1028.
27. Narita M, Hatano E, Arizono S, Miyagawa-Hayashino A, Isoda H, Kitamura K, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009;44(7):793-798.
28. Saito K, Kotake F, Ito N, Ozuki T, Mikami R, Abe K, et al. Gd- EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase. Magn Reson Med Sci. 2005;4(1):1-9.